Precision medicine as an approach to autoimmune diseases
暂无分享,去创建一个
[1] E. Katchalski‐Katzir,et al. Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] M. Fritzler,et al. Autoantibodies in SLE: prediction and the p value matrix , 2019, Lupus.
[3] M. Petri,et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. , 2009, Arthritis and rheumatism.
[4] K. Deane,et al. Rheumatoid Arthritis Prevention: Challenges and Opportunities to Change the Paradigm of Disease Management. , 2019, Clinical therapeutics.
[5] R. Cervera,et al. Moving towards a molecular taxonomy of autoimmune rheumatic diseases , 2018, Nature Reviews Rheumatology.
[6] Mary F. Wisniewski,et al. Diagnostic error in medicine: analysis of 583 physician-reported errors. , 2009, Archives of internal medicine.
[7] V. Holers,et al. The Natural History of Rheumatoid Arthritis. , 2019, Clinical therapeutics.
[8] U. Schneider,et al. Disease Specific Autoantibodies in Idiopathic Inflammatory Myopathies , 2019, Front. Neurol..
[9] M. Fritzler,et al. Redefining systemic lupus erythematosus — SMAARTT proteomics , 2018, Nature Reviews Rheumatology.
[10] M. Alarcón‐Riquelme,et al. Moving towards a molecular taxonomy of autoimmune rheumatic diseases , 2018, Nature Reviews Rheumatology.
[11] The Inaccuracy of Ocular Online Symptom Checkers-Googlers Beware. , 2019, JAMA ophthalmology.
[12] V. Holers,et al. Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis , 2019, Arthritis & Rheumatology.
[13] M. Mahler. Population-based screening for ACPAs: a step in the pathway to the prevention of rheumatoid arthritis? , 2017, Annals of the rheumatic diseases.
[14] S. Antinori,et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? , 2020, Clinical and experimental rheumatology.
[15] M. Panagopoulou,et al. Are the Origins of Precision Medicine Found in the Corpus Hippocraticum? , 2017, Molecular Diagnosis & Therapy.
[16] P. Tak,et al. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials , 2012, Annals of the rheumatic diseases.
[17] Y. Shoenfeld,et al. Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity , 2006, Lupus.
[18] Jessilyn Dunn,et al. Windows Into Human Health Through Wearables Data Analytics. , 2019, Current opinion in biomedical engineering.
[19] F. Chiarelli,et al. Prediction and prevention of type 1 diabetes in children , 2019, Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology.
[20] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[21] M. Gariboldi,et al. Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review , 2019, Journal of Endocrinological Investigation.
[22] Hangwi Tang,et al. Googling for a diagnosis—use of Google as a diagnostic aid: internet based study , 2006, BMJ : British Medical Journal.
[23] X. Mariette,et al. The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy , 2017, Annals of the rheumatic diseases.
[24] Y. Shoenfeld,et al. Tolerogenic dendritic cells in autoimmune diseases: crucial players in induction and prevention of autoimmunity. , 2010, Autoimmunity reviews.
[25] C. Denton,et al. Autoantibodies as predictive tools in systemic sclerosis , 2010, Nature Reviews Rheumatology.
[26] B. Cai,et al. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of systemic lupus erythematosus. , 2009, Rheumatology.
[27] M. Mahler,et al. Standardisation of myositis-specific antibodies: where are we today? , 2019, Annals of the Rheumatic Diseases.
[28] D. Solomon,et al. Medical Care Costs Associated With Rheumatoid Arthritis in the US: A Systematic Literature Review and Meta‐Analysis , 2018, Arthritis care & research.
[29] Azin Mirzazadeh,et al. Pathogenic and protective roles of cytokines in pemphigus: A systematic review. , 2020, Cytokine.
[30] E. Juengst,et al. Why Does the Shift from "Personalized Medicine" to "Precision Health" and "Wellness Genomics" Matter? , 2018, AMA journal of ethics.
[31] L. Gossec,et al. Detection of Flares by Decrease in Physical Activity, Collected Using Wearable Activity Trackers in Rheumatoid Arthritis or Axial Spondyloarthritis: An Application of Machine Learning Analyses in Rheumatology , 2019, Arthritis care & research.
[32] F. Ingegnoli,et al. COVID-19 infection and rheumatoid arthritis: Faraway, so close! , 2020, Autoimmunity Reviews.
[33] M. Petri,et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.
[34] V. Fineschi. Editorial: Personalized Medicine: A Positional Point of View about Precision Medicine and Clarity for Ethics of Public Health. , 2017, Current Pharmaceutical Biotechnology.
[35] Laura C. Cappelli,et al. Rheumatic immune-related adverse events from cancer immunotherapy , 2018, Nature Reviews Rheumatology.
[36] Belchin Kostov,et al. Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. , 2015, Autoimmunity reviews.
[37] C. Ding. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases , 2008, Expert opinion on biological therapy.
[38] C. Bombardier,et al. Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. , 2016, Rheumatology.
[39] D. Pisetsky. Evolving story of autoantibodies in systemic lupus erythematosus. , 2019, Journal of autoimmunity.
[40] J. Norris,et al. A molecular signature of preclinical rheumatoid arthritis triggered by dysregulated PTPN22. , 2016, JCI insight.
[41] G. Gulati,et al. Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus , 2018, Pediatric Nephrology.
[42] G. Kaplan,et al. Patient preferences for maintenance therapy in Crohn’s disease: A discrete-choice experiment , 2020, PloS one.
[43] Yu Song,et al. Wearable and Implantable Electronics: Moving toward Precision Therapy. , 2019, ACS nano.
[44] D. Kansagara,et al. Implementation Processes and Pay for Performance in Healthcare: A Systematic Review , 2016, Journal of general internal medicine.
[45] Alfio V Parisi,et al. A review on the ability of smartphones to detect ultraviolet (UV) radiation and their potential to be used in UV research and for public education purposes. , 2019, The Science of the total environment.
[46] U. Müller-Ladner,et al. Classification, categorization and essential items for digital ulcer evaluation in systemic sclerosis: a DeSScipher/European Scleroderma Trials and Research group (EUSTAR) survey , 2019, Arthritis Research & Therapy.
[47] L. Ou,et al. Biomarkers associating endothelial Dysregulation in pediatric-onset systemic lupus erythematous , 2019, Pediatric Rheumatology.
[48] Y. Shoenfeld. Primary biliary cirrhosis and autoimmune rheumatic diseases: prediction and prevention. , 1992, Israel journal of medical sciences.
[49] M. Rosenthal,et al. Beyond pay for performance--emerging models of provider-payment reform. , 2008, The New England journal of medicine.
[50] D. Bessis,et al. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis. , 2019, Acta dermato-venereologica.
[51] S. Bombardieri,et al. COVID-19: the new challenge for rheumatologists. , 2020, Clinical and experimental rheumatology.
[52] Eric J Topol,et al. High-performance medicine: the convergence of human and artificial intelligence , 2019, Nature Medicine.
[53] E. Matteson,et al. Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity. , 2019, Mayo Clinic proceedings.
[54] K. Latinis,et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. , 2012, Arthritis and rheumatism.
[55] V. Pascual,et al. Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus , 2020, Nature Medicine.
[56] G. Barturen,et al. SLE redefined on the basis of molecular pathways. , 2017, Best practice & research. Clinical rheumatology.
[57] D. Hilbert,et al. The discovery and development of belimumab: the anti-BLyS–lupus connection , 2012, Nature Biotechnology.
[58] W. Marlicz,et al. “Dr. Google, I am in Pain”—Global Internet Searches Associated with Pain: A Retrospective Analysis of Google Trends Data , 2020, International journal of environmental research and public health.
[59] Carl Shen,et al. Accuracy of a Popular Online Symptom Checker for Ophthalmic Diagnoses. , 2019, JAMA ophthalmology.
[60] O. Hamdy,et al. Patient-Driven Diabetes Care of the Future in the Technology Era. , 2019, Cell metabolism.
[61] I. Bruce,et al. Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach , 2018, Arthritis care & research.
[62] A. Aussy,et al. Dermatomyositis and Immune-Mediated Necrotizing Myopathies: A Window on Autoimmunity and Cancer , 2017, Front. Immunol..
[63] Manolis Tsiknakis,et al. Deep learning opens new horizons in personalized medicine , 2019, Biomedical reports.
[64] D. Furst,et al. Annual Medical Costs and Healthcare Resource Use in Patients with Systemic Sclerosis in an Insured Population , 2012, The Journal of Rheumatology.
[65] J. Harley,et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus , 2007, Lupus.
[66] S. Kalra,et al. Artificial Intelligence/Machine Learning in Diabetes Care , 2019, Indian journal of endocrinology and metabolism.
[67] H. Brunner,et al. THU0547 Real-world effectiveness of early aggressive treatment with biological disease-modifying antirheumatic drugs for the treatment of newly diagnosed polyarticular form of juvenile idiopathic arthritis , 2018, THURSDAY, 14 JUNE 2018.
[68] Francisco Herrera,et al. Deep Learning in Omics Data Analysis and Precision Medicine , 2019, Computational Biology.
[69] Andrea Zaccaria,et al. Considering patient clinical history impacts performance of machine learning models in predicting course of multiple sclerosis , 2020, PloS one.
[70] Y. Shoenfeld,et al. Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention. , 2015, Autoimmunity reviews.
[71] M. Dougados,et al. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases , 2019, RMD Open.
[72] Brian W Wu,et al. Redefining Health: The Evolution of Health Ideas from Antiquity to the Era of Value-Based Care , 2017, Cureus.
[73] M. Buch,et al. The 'therapeutic window' and treating to target in rheumatoid arthritis. , 2013, Clinical medicine.
[74] P. Badrinath,et al. Defining Health in the Era of Value-based Care: Lessons from England of Relevance to Other Health Systems , 2017, Cureus.
[75] B. Fu,et al. Identification of circular RNAs hsa_circ_0044235 and hsa_circ_0068367 as novel biomarkers for systemic lupus erythematosus , 2019, International journal of molecular medicine.
[76] Ami A. Shah,et al. Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease. , 2017, Clinical and experimental rheumatology.
[77] L. Trouw,et al. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. , 2012, Autoimmunity reviews.
[78] E. Topol,et al. The Pathway to Patient Data Ownership and Better Health. , 2017, JAMA.
[79] Y. Shoenfeld,et al. Immunomodulation for treatment and prevention of atherosclerosis. , 2002, Autoimmunity reviews.
[80] M. Ando,et al. Effectiveness of Lifestyle Intervention Using the Internet of Things System for Individuals with Early Type 2 Diabetes Mellitus , 2020, Internal medicine.
[81] P. Emery,et al. A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals , 2016, Current opinion in rheumatology.
[82] E. Topol. Digital medicine: empowering both patients and clinicians , 2016, The Lancet.
[83] J. Schoones,et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review , 2013, Annals of the rheumatic diseases.
[84] Shun-Chiao Chang,et al. Influence of Alcohol Consumption on the Risk of Systemic Lupus Erythematosus Among Women in the Nurses’ Health Study Cohorts , 2017, Arthritis care & research.
[85] N. Bansback,et al. Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review , 2019, The Journal of Rheumatology.
[86] Takanori Hasegawa,et al. The Potential Possibility of Symptom Checker , 2017, International journal of health policy and management.
[87] J. Rosenbloom,et al. Existing and novel biomarkers for precision medicine in systemic sclerosis , 2018, Nature Reviews Rheumatology.
[88] C. Allaart,et al. Brief Report: Clinical Trials Aiming to Prevent Rheumatoid Arthritis Cannot Detect Prevention Without Adequate Risk Stratification: A Trial of Methotrexate Versus Placebo in Undifferentiated Arthritis as an Example , 2017, Arthritis & rheumatology.
[89] R. Green,et al. Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) Family Study: rationale and design for a randomized controlled trial evaluating rheumatoid arthritis risk education to first-degree relatives. , 2014, Contemporary clinical trials.
[90] John M. Marzo,et al. How Accurate Are Patients at Diagnosing the Cause of Their Knee Pain With the Help of a Web-based Symptom Checker? , 2016, Orthopaedic journal of sports medicine.
[91] T. Huizinga,et al. The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis , 2015, Arthritis Research & Therapy.
[92] Kibum Kim,et al. The potential impact of monitoring disease activity biomarkers on rheumatoid arthritis outcomes and costs. , 2018, Personalized medicine.
[93] Yangqiu Li,et al. Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology , 2019, Cancer biology & medicine.
[94] A. Cope. Considerations for Optimal Trial Design for Rheumatoid Arthritis Prevention Studies. , 2019, Clinical therapeutics.
[95] Xu Chen,et al. Potential protein biomarkers for systemic lupus erythematosus determined by bioinformatics analysis , 2019, Comput. Biol. Chem..
[96] J. Sparks,et al. Mobile Apps for Individuals With Rheumatoid Arthritis: A Systematic Review , 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.
[97] Sharareh R. Niakan Kalhori,et al. Artificial Intelligence Applications in Type 2 Diabetes Mellitus Care: Focus on Machine Learning Methods , 2019, Healthcare informatics research.
[98] G. T. Sharrer. Personalized Medicine: Ethical Aspects. , 2017, Methods in molecular biology.
[99] A. Cope,et al. Autoantibodies targeting TLR and SMAD pathways define new subgroups in systemic lupus erythematosus. , 2018, Journal of autoimmunity.
[100] R. Moscicki,et al. Drug‐Development Challenges for Small Biopharmaceutical Companies , 2017, The New England journal of medicine.
[101] E. Karlson,et al. Impact of Cyclic Citrullinated Peptide Antibody Level on Progression to Rheumatoid Arthritis in Clinically Tested Cyclic Citrullinated Peptide Antibody–Positive Patients Without Rheumatoid Arthritis , 2019, Arthritis care & research.
[102] J. Norris,et al. Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment , 2015, Rheumatology.
[103] Rostyslav V Bubnov,et al. Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine? , 2017, EPMA Journal.
[104] S. Kauffman,et al. Study design and the drug development process. , 2014, JAMA.
[105] M. Freedman,et al. Precision medicine in the multiple sclerosis clinic: Selecting the right patient for the right treatment , 2020, Multiple sclerosis.
[106] E. Cummins,et al. Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis , 2013, BMJ Open.
[107] M. Fritzler,et al. Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care , 2016, Lupus.
[108] A. Clarke,et al. Socioeconomic consequences of systemic lupus erythematosus , 2017, Current opinion in rheumatology.
[109] Benjamin Marshall Davies,et al. A Novel Insight Into the Challenges of Diagnosing Degenerative Cervical Myelopathy Using Web-Based Symptom Checkers , 2019, Journal of medical Internet research.
[110] D. Marshall,et al. Qualitative Study of Treatment Preferences for Rheumatoid Arthritis and Pharmacotherapy Acceptance: Indigenous Patient Perspectives , 2020, Arthritis care & research.
[111] May Y. Choi,et al. The Utilization of Autoantibodies in Approaches to Precision Health , 2018, Front. Immunol..
[112] L. Trouw,et al. Rheumatoid arthritis: Autoantibody testing to predict response to therapy in RA , 2016, Nature Reviews Rheumatology.
[113] N. Rose. Prediction and Prevention of Autoimmune Disease , 2007, Annals of the New York Academy of Sciences.
[114] William G. Dixon,et al. Using technology to support clinical care and research in rheumatoid arthritis , 2018, Current opinion in rheumatology.
[115] A. Filer,et al. The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? , 2015, Annals of the rheumatic diseases.
[116] J. Seidman,et al. Novel Therapies for Prevention and Early Treatment of Cardiomyopathies. , 2019, Circulation research.
[117] K. Deane. Preclinical Rheumatoid Arthritis and Rheumatoid Arthritis Prevention , 2018, Current Rheumatology Reports.
[118] Brenden Rossin,et al. Augmented versus artificial intelligence for stratification of patients with myositis , 2019, Annals of the Rheumatic Diseases.
[119] M. Guiguet,et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies , 2018, JAMA neurology.
[120] W. Dixon,et al. 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis , 2018, Annals of the rheumatic diseases.
[121] I. Bruce,et al. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach , 2020, Arthritis care & research.
[122] E. Smolewska,et al. Tocilizumab in the treatment of systemic-onset juvenile idiopathic arthritis – single-centre experience , 2018, Reumatologia.
[123] T. Niewold,et al. Lessons from precision medicine in rheumatology , 2020, Multiple sclerosis.
[124] G. Simons,et al. Are online symptoms checkers useful for patients with inflammatory arthritis? , 2016, BMC Musculoskeletal Disorders.
[125] E. Smolewska,et al. In the Pursuit of Methotrexate Treatment Response Biomarker in Juvenile Idiopathic Arthritis—Are We Getting Closer to Personalised Medicine? , 2017, Current Rheumatology Reports.
[126] D. Cortese,et al. Pay-for-performance or pay for value? , 2007, Mayo Clinic proceedings.
[127] E. Karlson,et al. Impact and Timing of Smoking Cessation on Reducing Risk of Rheumatoid Arthritis Among Women in the Nurses’ Health Studies , 2019, Arthritis care & research.
[128] S. Nagpal,et al. Cohort profile of a US military population for evaluating pre-disease and disease serological biomarkers in rheumatoid and reactive arthritis: Rationale, organization, design, and baseline characteristics , 2020, Contemporary clinical trials communications.
[129] V. Ronca,et al. Prognostic models in primary biliary cholangitis. , 2018, Journal of autoimmunity.
[130] G. Burmester. Rheumatology 4.0: big data, wearables and diagnosis by computer , 2018, Annals of the rheumatic diseases.
[131] V. Ronca,et al. Precision medicine in primary biliary cholangitis , 2019, Journal of digestive diseases.
[132] Y. Shoenfeld,et al. Readability of Wikipedia Pages on Autoimmune Disorders: Systematic Quantitative Assessment , 2017, Journal of medical Internet research.
[133] L. Arnaud,et al. Advances in the treatment of systemic lupus erythematosus: From back to the future, to the future and beyond. , 2019, Joint, bone, spine : revue du rhumatisme.
[134] Jennifer P D'Auria,et al. Googling for health information. , 2012, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.
[135] N. Rose. Prediction and Prevention of Autoimmune Disease in the 21st Century: A Review and Preview. , 2016, American journal of epidemiology.
[136] John B. Watkins,et al. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[137] N. Olsen,et al. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial , 2018, Trials.
[138] Zhi Geng,et al. Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine , 2019, Public Health Genomics.
[139] Jeffrey Dean,et al. Machine Learning in Medicine , 2019, The New England journal of medicine.
[140] L. Hood,et al. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. , 2012, New biotechnology.
[141] P. V. van Riel,et al. Patient Self-Management and Tracking: A European Experience. , 2019, Rheumatic diseases clinics of North America.
[142] A. Silman,et al. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study , 2018, Annals of the rheumatic diseases.
[143] J. Ingelfinger,et al. Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention. , 2019, The New England journal of medicine.
[144] Ritesh G. Menezes,et al. Personalized Medicine in a New Genomic Era: Ethical and Legal Aspects , 2017, Sci. Eng. Ethics.
[145] Y. Allenbach,et al. Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. , 2019, Autoimmunity reviews.
[146] J. Pollard,et al. Conduction block in immune‐mediated neuropathy: paranodopathy versus axonopathy , 2019, European journal of neurology.
[147] E. Topol,et al. Disruptive Innovation in Laboratory Medicine. , 2015, Clinical Chemistry.
[148] J. Norris,et al. Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE , 2019, Lupus.
[149] E. Topol,et al. Patient Data Ownership-Reply. , 2018, Journal of the American Medical Association (JAMA).
[150] V. Pascual,et al. Unique Sjögren's syndrome patient subsets defined by molecular features. , 2020, Rheumatology.
[151] Xiao Li,et al. B Cell-Related Circulating MicroRNAs With the Potential Value of Biomarkers in the Differential Diagnosis, and Distinguishment Between the Disease Activity and Lupus Nephritis for Systemic Lupus Erythematosus , 2018, Front. Immunol..
[152] A. Tincani,et al. Autoantibodies’ titre modulation by anti-BlyS treatment in systemic lupus erythematosus , 2019, Lupus.
[153] C. Ruiz,et al. Vitamin D and autoimmune diseases. , 2019, Life sciences.
[154] R. Green,et al. Disclosure of Personalized Rheumatoid Arthritis Risk Using Genetics, Biomarkers, and Lifestyle Factors to Motivate Health Behavior Improvements: A Randomized Controlled Trial , 2018, Arthritis care & research.
[155] D. Tang,et al. Advances in applying of multi-omics approaches in the research of systemic lupus erythematosus , 2020, International reviews of immunology.
[156] I. Nishino,et al. Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. , 2020, Autoimmunity reviews.
[157] L. Klareskog,et al. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting , 2016, Nature Reviews Immunology.
[158] John Nelson,et al. Activity level classification algorithm using SHIMMER™ wearable sensors for individuals with rheumatoid arthritis , 2011, 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[159] Hailiang Liu,et al. Novel biomarkers containing citrullinated peptides for diagnosis of systemic lupus erythematosus using protein microarrays. , 2019, Clinical and experimental rheumatology.
[160] P. Roux‐Lombard,et al. Value of Biomarkers in the Prevention of Rheumatoid Arthritis , 2017, Clinical pharmacology and therapeutics.
[161] Marcus Woo,et al. An AI boost for clinical trials , 2019, Nature.
[162] E. Reis,et al. Evaluation of potential biomarkers for the diagnosis and monitoring of Systemic Lupus Erythematosus using the Cytometric Beads Array (CBA). , 2019, Clinica chimica acta; international journal of clinical chemistry.
[163] T. Huizinga,et al. Triple Positivity for Anti–Citrullinated Protein Autoantibodies, Rheumatoid Factor, and Anti–Carbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis , 2018, Arthritis & rheumatology.
[164] A. Elliot,et al. Internet-based remote health self-checker symptom data as an adjuvant to a national syndromic surveillance system , 2015, Epidemiology and Infection.
[165] M. Fritzler,et al. Detection of myositis-specific antibodies: additional notes , 2018, Annals of the rheumatic diseases.
[166] J. Norris,et al. Less than 7 hours of sleep per night is associated with transitioning to systemic lupus erythematosus , 2018, Lupus.
[167] K. Raza,et al. Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives , 2019, RMD Open.
[168] Robert N. Anderson,et al. Potentially Preventable Deaths from the Five Leading Causes of Death — United States, 2008–2010 , 2014, MMWR. Morbidity and mortality weekly report.
[169] C. Cobelli,et al. Continuous Glucose Monitoring Linked to an Artificial Intelligence Risk Index: Early Footprints of Intraventricular Hemorrhage in Preterm Neonates. , 2019, Diabetes technology & therapeutics.
[170] M. Fritzler. Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing. , 2016, Autoimmunity reviews.
[171] M. Petri,et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response , 2012, Annals of the rheumatic diseases.
[172] P. V. van Diest,et al. Ethical considerations for modern molecular pathology , 2018, The Journal of pathology.
[173] C. Langefeld,et al. Association of SLCO1B1 *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients , 2019, ACR open rheumatology.
[174] Eric J Topol,et al. Information and Artificial Intelligence. , 2018, Journal of the American College of Radiology : JACR.
[175] S. Jimenez,et al. Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis , 2018, Rheumatology.
[176] J. Krischer,et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. , 2019, The New England journal of medicine.
[177] Jessilyn Dunn,et al. Wearables and the medical revolution. , 2018, Personalized medicine.
[178] Md. Asiful Islam,et al. Gene Therapy Approaches in an Autoimmune Demyelinating Disease: Multiple Sclerosis. , 2020, Current gene therapy.
[179] S. Steinhubl,et al. Advanced and Accurate Mobile Health Tracking Devices Record New Cardiac Vital Signs , 2018, Hypertension.
[180] G. Mells,et al. Individualizing Care: Management Beyond Medical Therapy. , 2018, Clinics in liver disease.
[181] Claudia Douglas,et al. The HackensackUMC Value-Based Care Model: Building Essentials for Value-Based Purchasing , 2016, Nursing administration quarterly.
[182] Michael A. Smith,et al. SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus , 2019, Scientific Reports.
[183] D. Hayes,et al. A temporary indwelling intravascular aphaeretic system for in vivo enrichment of circulating tumor cells , 2019, Nature Communications.
[184] J. Manning,et al. Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study , 2018, Scandinavian journal of rheumatology.
[185] J. Vallat,et al. Autoimmune nodo-paranodopathies of peripheral nerve: the concept is gaining ground , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[186] G. Iskrov,et al. Social/economic costs and health-related quality of life in patients with scleroderma in Europe , 2016, The European Journal of Health Economics.
[187] G. Espinosa,et al. Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting , 2019, Scandinavian journal of rheumatology.
[188] Ami A. Shah,et al. Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer , 2018, Annals of the rheumatic diseases.
[189] F. Berenbaum,et al. Mobile Health Apps for Self-Management of Rheumatic and Musculoskeletal Diseases: Systematic Literature Review , 2019, JMIR mHealth and uHealth.
[190] A. Zwinderman,et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study , 2018, Annals of the rheumatic diseases.
[191] Nathan Foulquier,et al. How Health Information Technologies and Artificial Intelligence May Help Rheumatologists in Routine Practice , 2019, Rheumatology and Therapy.
[192] J. Norris,et al. Genetic and environmental risk factors for rheumatoid arthritis. , 2017, Best practice & research. Clinical rheumatology.
[193] C. Denton,et al. Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis , 2020, Arthritis & rheumatology.
[194] W. Alkema,et al. Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels. , 2020, Autoimmunity reviews.
[195] Ami A. Shah,et al. More Than Skin Deep: Bringing Precision Medicine to Systemic Sclerosis , 2020, Arthritis & rheumatology.
[196] C. Gidengil,et al. Evaluation of symptom checkers for self diagnosis and triage: audit study , 2015, BMJ : British Medical Journal.
[197] W. Riley,et al. Precision Public Health for the Era of Precision Medicine. , 2016, American journal of preventive medicine.
[198] G. Hazlewood. Measuring Patient Preferences: An Overview of Methods with a Focus on Discrete Choice Experiments. , 2018, Rheumatic diseases clinics of North America.
[199] S. Doyle-Lindrud,et al. Watson will see you now: a supercomputer to help clinicians make informed treatment decisions. , 2015, Clinical journal of oncology nursing.
[200] G. Gibson,et al. PART of the WHOLE: A Case Study in Wellness-Oriented Personalized Medicine , 2015, The Yale journal of biology and medicine.
[201] Anjuli Kannan,et al. Automatically Charting Symptoms From Patient-Physician Conversations Using Machine Learning. , 2019, JAMA internal medicine.
[202] Neil Mehta,et al. Policy Implications of Artificial Intelligence and Machine Learning in Diabetes Management , 2020, Current Diabetes Reports.
[203] Eric J. Topol,et al. The big medical data miss: challenges in establishing an open medical resource , 2015, Nature Reviews Genetics.
[204] A. Finckh,et al. Is the prevention of rheumatoid arthritis possible? , 2020, Clinical Rheumatology.
[205] B. Fu,et al. Circular RNAs hsa_circ_0000479 in peripheral blood mononuclear cells as novel biomarkers for systemic lupus erythematosus , 2020, Autoimmunity.
[206] E. Pezzarini,et al. Oxidative stress, inflammation and disease activity biomarkers in lupus nephropathy , 2020, Lupus.
[207] P. Emery,et al. Prevention and cure: The major unmet needs in the management of rheumatoid arthritis. , 2019, Journal of autoimmunity.
[208] P. Lipsky,et al. New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti‐DNA , 2016, Arthritis & rheumatology.
[209] P. Sfikakis,et al. The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. , 2020, Autoimmunity reviews.
[210] N. Olsen,et al. Emerging technologies in autoantibody testing for rheumatic diseases , 2017, Arthritis Research & Therapy.